Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Analysts have provided diverse opinions on Regeneron Pharmaceuticals (NASDAQ:REGN) with a mix of bullish to bearish ratings over the past quarter. The average 12-month price target for REGN has been raised to $1068.58, indicating a positive outlook. The company's financials show a market capitalization above industry average, but it lags in revenue growth, net margin, ROE, and ROA compared to its peers. However, its low debt-to-equity ratio is seen positively.
March 26, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals has received mixed analyst ratings but an increased average 12-month price target, indicating a positive sentiment. Financial indicators show strengths and weaknesses, with a notable low debt-to-equity ratio.
The increase in the average 12-month price target for REGN, despite mixed analyst ratings, suggests a generally positive outlook on the stock. Financially, the company's strong market cap and low debt-to-equity ratio are positive indicators, although it lags in some performance metrics compared to peers. This analysis considers the impact of analyst sentiments and financial health on the stock's short-term performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100